BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 15531029)

  • 1. Effectiveness of a publicly funded pneumococcal vaccination program against invasive pneumococcal disease among the elderly in Victoria, Australia.
    Andrews RM; Counahan ML; Hogg GG; McIntyre PB
    Vaccine; 2004 Nov; 23(2):132-8. PubMed ID: 15531029
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The cost-effectiveness of pneumococcal conjugate vaccination in Australia.
    Butler JR; McIntyre P; MacIntyre CR; Gilmour R; Howarth AL; Sander B
    Vaccine; 2004 Mar; 22(9-10):1138-49. PubMed ID: 15003641
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Failure to vaccinate or failure of vaccine? Effectiveness of the 23-valent pneumococcal polysaccharide vaccine program in Indigenous adults in the Northern Territory of Australia.
    Moberley S; Krause V; Cook H; Mulholland K; Carapetis J; Torzillo P; Andrews R
    Vaccine; 2010 Mar; 28(11):2296-301. PubMed ID: 20116468
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protective effects of the 23-valent pneumococcal polysaccharide vaccine in the elderly population: the EVAN-65 study.
    Vila-Córcoles A; Ochoa-Gondar O; Hospital I; Ansa X; Vilanova A; Rodríguez T; Llor C;
    Clin Infect Dis; 2006 Oct; 43(7):860-8. PubMed ID: 16941367
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changing epidemiology of invasive pneumococcal disease among White Mountain Apache persons in the era of the pneumococcal conjugate vaccine.
    Lacapa R; Bliss SJ; Larzelere-Hinton F; Eagle KJ; McGinty DJ; Parkinson AJ; Santosham M; Craig MJ; O'Brien KL
    Clin Infect Dis; 2008 Aug; 47(4):476-84. PubMed ID: 18627249
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of surveillance data to estimate the effectiveness of the 7-valent conjugate pneumococcal vaccine in children less than 5 years of age over a 9 year period.
    De Serres G; Pilishvili T; Link-Gelles R; Reingold A; Gershman K; Petit S; Farley MM; Harrison LH; Lynfield R; Bennett NM; Baumbach J; Thomas A; Schaffner W; Beall B; Whitney C; Moore M
    Vaccine; 2012 Jun; 30(27):4067-72. PubMed ID: 22525797
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Invasive pneumococcal disease among White Mountain Apache adults, 1991-2005.
    Bliss SJ; Larzalere-Hinton F; Lacapa R; Eagle KR; Frizzell F; Parkinson A; Reid R; Craig M; Santosham M; O'Brien KL
    Arch Intern Med; 2008 Apr; 168(7):749-55. PubMed ID: 18413558
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease--United States, 1998-2003.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2005 Sep; 54(36):893-7. PubMed ID: 16163262
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduction in the incidence of invasive pneumococcal disease after general vaccination with 7-valent pneumococcal conjugate vaccine in Germany.
    Rückinger S; van der Linden M; Reinert RR; von Kries R; Burckhardt F; Siedler A
    Vaccine; 2009 Jun; 27(31):4136-41. PubMed ID: 19406190
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of vaccine coverage following the introduction of a publicly funded pneumococcal vaccine program for the elderly in Victoria, Australia.
    Andrews RM
    Vaccine; 2005 Apr; 23(21):2756-61. PubMed ID: 15780723
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Surveillance for invasive pneumococcal disease during 2000-2005 in a population of children who received 7-valent pneumococcal conjugate vaccine.
    Black S; France EK; Isaacman D; Bracken L; Lewis E; Hansen J; Fireman B; Austrian R; Graepel J; Gray S; Klein NP
    Pediatr Infect Dis J; 2007 Sep; 26(9):771-7. PubMed ID: 17721369
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pediatric hospitalization for pneumococcal diseases preventable by 7-valent pneumococcal conjugate vaccine in Hong Kong.
    Ho PL; Chiu SS; Chow FK; Mak GC; Lau YL
    Vaccine; 2007 Sep; 25(39-40):6837-41. PubMed ID: 17714837
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevention of community-acquired pneumonia among a cohort of hospitalized elderly: benefit due to influenza and pneumococcal vaccination not demonstrated.
    Skull SA; Andrews RM; Byrnes GB; Kelly HA; Nolan TM; Brown GV; Campbell DA
    Vaccine; 2007 Jun; 25(23):4631-40. PubMed ID: 17478015
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of a 2+1 dose schedule pneumococcal conjugate vaccination programme on invasive pneumococcal disease among children in Norway.
    Vestrheim DF; Løvoll O; Aaberge IS; Caugant DA; Høiby EA; Bakke H; Bergsaker MR
    Vaccine; 2008 Jun; 26(26):3277-81. PubMed ID: 18456376
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of pneumococcal vaccination of older people: a study in 5 western European countries.
    Ament A; Baltussen R; Duru G; Rigaud-Bully C; de Graeve D; Ortqvist A; Jönsson B; Verhaegen J; Gaillat J; Christie P; Cifre AS; Vivas D; Loiseau C; Fedson DS
    Clin Infect Dis; 2000 Aug; 31(2):444-50. PubMed ID: 10987703
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of pneumococcal vaccination for elderly people in Catalonia, Spain: a case-control study.
    Dominguez A; Salleras L; Fedson DS; Izquierdo C; Ruiz L; Ciruela P; Fenoll A; Casal J
    Clin Infect Dis; 2005 May; 40(9):1250-7. PubMed ID: 15825026
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Invasive pneumococcal disease in Australia, 2001.
    Roche P; Krause V;
    Commun Dis Intell Q Rep; 2002; 26(4):505-19. PubMed ID: 12549516
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of indirect (herd) protection on the cost-effectiveness of pneumococcal conjugate vaccine.
    Isaacman DJ; Strutton DR; Kalpas EA; Horowicz-Mehler N; Stern LS; Casciano R; Ciuryla V
    Clin Ther; 2008 Feb; 30(2):341-57. PubMed ID: 18343273
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Vaccination of the elderly against pneumococcal disease is cost-efficient. Mass vaccination of all aged 65 and over is recommended].
    Ortqvist A; Jönsson B; Baltussen R; Ament A
    Lakartidningen; 2000 Nov; 97(45):5120-5. PubMed ID: 11116891
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adults with invasive pneumococcal disease: missed opportunities for vaccination.
    Kyaw MH; Greene CM; Schaffner W; Ray SM; Shapiro M; Barrett NL; Gershman K; Craig AS; Roberson A; Zell ER; Schuchat A; Bennett NM; Whitney CG;
    Am J Prev Med; 2006 Oct; 31(4):286-92. PubMed ID: 16979452
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.